The new melanoma staging system

Seminars in Cutaneous Medicine and Surgery

Volumn 22, Issue 1, 2003, Pages 42-54

  Balch, Charles M ^a,b   Sober, Arthur J ^l   Soong, Seng jaw ^d   Gershenwald, Jeffrey E ⁱ   Buzaid, Antonio C ^c   Atkins, Michael B ^e   Cascinelli, Natale ^f   Coit, Daniel G ^g   Fleming, Irvin D ^h   Houghton Jr , Alan ^g   Kirkwood, John M ^j   McMasters, Kelly M ^k   Mihm Jr , Martin F ^l   Morton, Donald L ^m   Reintgen, Douglas S ⁿ   Ross, Merrick I ⁱ   Thompson, John A ^o   Thompson, John F ^p  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

^c HOSPITAL SÍRIO LIBANÊS   (Brazil)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^f NATIONAL CANCER INSTITUTE   (Italy)

^g MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^h Methodist Hospital Cancer Center   (United States)

ⁱ UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^j UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^k UNIVERSITY OF LOUISVILLE HOSPITAL   (United States)

^l MASSACHUSETTS GENERAL HOSPITAL   (United States)

^m JOHN WAYNE CANCER INSTITUTE   (United States)

ⁿ H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^o UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^p UNIVERSITY OF SYDNEY   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; HISTOPATHOLOGY; HUMAN; LYMPH NODE METASTASIS; MEDICAL SOCIETY; MELANOMA; METASTASIS; PROGNOSIS; REVIEW;

HUMANS; LYMPHATIC METASTASIS; MELANOMA; NEOPLASM INVASIVENESS; NEOPLASM STAGING; SKIN NEOPLASMS; UNITED STATES;

EID: 0037693973     PISSN: 10855629     EISSN: None     Source Type: Journal    
DOI: 10.1053/sder.2003.50004     Document Type: Review

References (63)

1. Balch CM, Buzaid AC, Atkins MB, et al: A new American Joint Committee on Cancer staging system for cutaneous melanoma. Cancer 88:1484-1491, 2000
2. Balch C, Buzaid AC, Soong SJ, et al: Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 19:3635-3648, 2001
3. Gershenwald JE, Buzaid AC: Staging Systems for Cutaneous Melanoma, in Thompson JA (ed): Cutaneous Melanoma, 2002
4. Greene F, Page DL, Fleming ID, et al: AJCC Cancer Staging Manual (ed 6). New York, NY, Springer-Verlag, 2002
5. Balch C, Soong SJ, Gershenwald JE, et al: Prognostic factors analysis of 17,600 melanoma patients. Validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 19:3622-3634, 2001
6. Essner R, Conforti A, Kelley MC, et al: Efficacy of lymphatic mapping, sentinel lymphadenectomy, and selective complete lymph node dissection as a therapeutic procedure for early-stage melanoma. Ann Surg Oncol 6:442-449, 1999
7. Morton DL, Wanek L, Nizze JA, et al: Improved long-term survival after lymphadenectomy of melanoma metastatic to regional nodes. Analysis of prognostic factors in 1134 patients from the John Wayne Cancer Clinic. Ann Surg 214: 491-9; discussion 499-501, 1991
8. Morton DL, Thompson JF, Essner R, et al: Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: a multicenter trial. Multicenter Selective Lymphadenectomy Trial Group. Ann Surg 230:453-463; discussion 463-465, 1999
9. Morton DL, Chan AD: Current status of intraoperative lymphatic mapping and sentinel lymphadenectomy for melanoma: Is it standard of care? J Am Coll Surg 189:214-223, 1999
10. Gershenwald JE, Tseng CH, Thompson W, et al: Improved sentinel lymph node localization in patients with primary melanoma with the use of radiolabeled colloid. Surgery 124:203-210, 1998
11. Gershenwald JE, Thompson W, Mansfield PF, et al: Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol 17:976-983, 1999
12. Gershenwald JE, Mansfield PF, Lee JE, et al: The role for lymphatic mapping and sentinel lymph node biopsy in patients with thick (> 4 mm) primary melanoma. Ann Surg Oncol 7:160-165, 2000
13. Gershenwald JE, Prieto V, Colome-Grimmer MI, et al: The prognostic significance of microscopic tumor burden in 925 melanoma patients undergoing sentinel lymph node biopsy. Proc Am Soc Clin Oncol 19:551a, 2000 (abstr)
14. Mraz-Gernhard S, Sagebiel RW, Kashani-Sabet M, et al: Prediction of sentinel lymph node micrometastasis by histological features in primary cutaneous malignant melanoma. Arch Derm 134:983-987, 1998
15. O'Brien CJ, Uren RF, Thompson JF, et al: Prediction of potential metastatic sites n cutaneous head and neck melanoma using lymphoscintigraphy. Am J Surg 170:461-466, 1995
16. Pu LL, Cruse CW, Wells KE, et al: Lymphatic mapping and sentinel lymph node biopsy in patients with melanoma of the lower extremity [see comments]. Plast Reconstr Surg 104:964-969, 1999
17. Wagner JD, Gordon MS, Chuang TY, et al: Predicting sentinel and residual lymph node basin disease after sentinel lymph node biopsy for melanoma. Cancer 89:453-462, 2000
18. Yu LL, Flotte TJ, Tanabe KK, et al: Detection of microscopic melanoma metastases in sentinel lymph nodes. Cancer 86:617-627, 1999
19. Balch CM, Murad TM, Soong SJ, et al: A multifactorial analysis of melanoma: prognostic histopathological features comparing Clark's and Breslow's staging methods. Ann Surg 188:732-742, 1978
20. Balch CM, Soong SJ, Murad TM, et al: A multifactorial analysis of melanoma. II. Prognostic factors in patients with stage I (localized) melanoma. Surgery 86:343-351, 1979
21. Balch CM, Murad TM, Soong SJ, et al: Tumor thickness as a guide to surgical management of clinical stage 1 melanoma patients. Cancer 43:883-888, 1979
22. Balch CM: Cutaneous melanoma: Prognosis and treatment results worldwide. Semin Surg Oncol 8:400-414, 1992
23. Breslow A, Macht SD: Evaluation of prognosis in Stage 1 cutaneous melanoma. Plast Reconstr Surg 61:342-346, 1978
24. Haffner AC, Garbe C, Burg G, et al: The prognosis of primary and metastasising melanoma. An evaluation of the TNM classification in 2,495 patients. Br J Cancer 66:856-861, 1992
25. Buttner P, Garbe C, Bertz J, et al: Primary cutaneous melanoma. Optimized cutoff points of tumor thickness and importance of Clark's level for prognostic classification. Cancer 75:2499-2506, 1995.
26. Balch CM, Wilkerson JA, Murad TM, et al: The prognostic significance of ulceration of cutaneous melanoma. Cancer 45:3012-3017, 1980
27. McGovern VJ, Shaw HM, Milton GW, et al: Ulceration and prognosis in cutaneous malignant melanoma. Histopathology 6:399-407, 1982
28. Clark WH, Jr., From L, Bernardino EA, Mihm MC: The histogenesis and biological behavior of primary human malignant melanoma of the skin. Cancer Res 29:705-727, 1969
29. Cascinelli N, Zurrida S, Galirnberti V, et al: Acral lentiginous melanoma. A histological type without prognostic significance. J Dermatol Surg Oncol 20:817-822, 1994
30. McGovern VJ, Shaw HM, Milton GW, et al: Is malignant melanoma arising in a Hutchinson's melanotic freckle a separate disease entity? Histopathology 4:235-242, 1980
31. Kuchelmeister C, Schaumburg-Lever G, Garbe C: Acral cutaneous melanoma in caucasians: clinical features, histopathology and prognosis in 112 patients. Br J Dermatol 143:275-280, 2000
32. Urist MM, Balch CM, Soong SJ, et al: Head and neck melanoma in 534 clinical Stage 1 patients. A prognostic factors analysis and results of surgical treatment. Ann Surg 200:769-775, 1984
33. Slingluff CL, J., Vollmer R, Seigler HF: Acral melanoma: A review of 185 patients with identification of prognostic variables. J Surg Oncol 45:91-98, 1990
34. Garbe CBP, Bertz J, et al: Primary cutaneous melanoma: Prognostic classification of anatomic location. Cancer 75:2492, 1995
35. Carlson J, Dickersin GR, Sober AJ, et al: Desmoplastic neurotropic melanoma. Cancer 75:478, 1995
36. Quinn MJ, Crotty KA, Thompson JF, et al: Desmoplastic and desrnoplastic neurotropic melanoma: Experience with 280 patients. Cancer 83:1128-1135, 1998
37. Balch CM, Soong SJ, Murad TM, et al: A multifactorial analysis of melanoma: III. Prognostic factors in melanoma patients with lymph node metastases (stage 11). Ann Surg 193: 377-388, 1981
38. Bevilacqua RG, Coit DG, Rogatko A, et al: Axillary dissection in melanoma: Prognostic variables in node-positive patients. Ann Surg 212:125-131, 1990
39. Buzaid AC, Ross MI, Balch CM, et al: Critical analysis of the current American Joint Committee on Cancer staging system for cutaneous melanoma and proposal of a new staging system [see comments]. J Clin Oncol 15:1039-1051, 1997
40. Calabro A, Singletary SE, Balch CM: Patterns of relapse in 1001 consecutive patients with melanoma nodal metastases. Arch Surg 124:1051-1055, 1989
41. Coit DG, Rogatko A, Brennan MF: Prognostic factors in patients with melanoma metastatic to axillary or inguinal lymph nodes. A multivariate analysis. Ann Surg 214:627-636, 1991
42. Coit D: Prognostic factors in patients with melanoma metastic to regional nodes. Surg Oncol Clin North Am 1:281-295, 1992
43. Day C, Sober AJ, Lew RA, et al: Malignant melanoma patients with positive nodes and relatively good prognoses: Microstaging retains prognostic significance in clinical Stage I melanoma patients with metastases to regional nodes. Cancer 47:955-962, 1981
44. Drepper H, Biess B, Hofherr B, et al: The prognosis of patients with stage III melanoma. Cancer 71:1239-1246, 1993
45. Slingluff CL, Jr, Vollmer R, Seigler HF: Stage II malignant melanoma: Presentation of a prognostic model and an assessment of specific active immunotherapy in 1,273 patients. J Surg Oncol 39:139-147, 1988
46. Gershenwald JE, Colome MI, Lee JE, et al: Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma. J Clin Oncol 16:2253-2260, 1998
47. Dale PS, Foshag LJ, Wanek LA, et al: Metastasis of primary melanoma to two separate lymph node basins: prognostic significance. Ann Surg Oncol 4:13-18, 1997
48. Shaw HM, Balch CM, Soong SJ, et al: Prognostic histopathological factors in malignant melanoma. Pathology 17:271-274, 1985
49. Koh HK, Sober AJ, Day CL, Jr, et al: Prognosis of clinical stage I melanoma patients with positive elective regional node dissection. J Clin Oncol 4:1238-1244, 1986
50. Balch CM, Soong SJ, Murad TM, et al: A multifactorial analysis of melanoma. IV. Prognostic factors in 200 melanoma patients with distant metastases (stage III). J Clin Oncol 1:126-34, 1983
51. Barth A, Wanek LA, Morton DL: Prognostic factors in 1,521 melanoma patients with distant metastases. J Am Coll Surg 181:193-201, 1995
52. Keilholz U, Conradt C, Legha SS, et al: Results of interleukin-2-based treatment in advanced melanoma: A case record-based analysis of 631 patients. J Clin Oncol 16:2921-2929, 1998
53. Eton O, Legha SS, Moon TE, et al: Prognostic factors for survival of patients treated systemically for disseminated melanoma. J Clin Oncol 16:1103-1111, 1998
54. Brand CU, Ellwanger U, Stroebel W, et al: Prolonged survival of 2 years or longer f or patients with disseminated melanoma. Cancer 79:2345-2353, 1997
55. Azzola M, Shaw HM, Thompson JF, et al: Tumor mitotic rate is a more powerful prognostic indicator than ulceration in patients with primary cutaneous melanoma. An analysis of 3661 patients from a single center. Cancer 2003 (in press)
56. Bostick PJ, Morton DL, Turner RR, et al: Prognostic significance of occult metastases detected by sentinel lymphadenectomy and reverse transcriptase-polymerase chain reaction in early-stage melanoma patients. J Clin Oncol 17:3238-3244, 1999
57. Curry BJ, Farrelly M, Hersey P: Evaluation of S-100beta assays for the prediction of recurrence and prognosis in patients with AJCC stage 1-III melanoma. Melanoma Res 9:557-567, 1999
58. Deichmann M, Benner A, Bock M, et al: S100-Beta, melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on Cancer stage IV melanoma. J Clin Oncol 17:1891-1896, 1999
59. Kelley MC, Ollila DW, Morton DL: Lymphatic mapping and sentinel lymphadenectomy for melanoma. Semin Surg Oncol 14:283-290, 1998
60. van der Velde-Zimmermann D, Schipper ME, de Weger RA, et al: Sentinel node biopsies in melanoma patients: A protocol for accurate, efficient, and cost-effective analysis by preselection for immunohistochemistry on the basis of Tyr-PCR. Ann Surg Oncol 7:51-54, 2000
61. Van der Velde-Zimmermann D, Roijers JF, Bouwens-Rombouts A, et al: Molecular test for the detection of tumor cells in blood and sentinel nodes of melanoma patients. Am J Pathol 149:759-764, 1996
62. von Schoultz E, Hansson LO, Djureen E, et al: Prognostic value of serum analyses of S-100 beta protein in malignant melanoma. Melanoma Res 6:133-137, 1996
63. Shivers SC, Wang X, Li W, et al: Molecular staging of malignant melanoma: correlation with clinical outcome. JAMA 280:1410-1415, 1998